285 related articles for article (PubMed ID: 27472710)
41. Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.
Hamilton DH; Roselli M; Ferroni P; Costarelli L; Cavaliere F; Taffuri M; Palena C; Guadagni F
Endocr Relat Cancer; 2016 Oct; 23(10):783-796. PubMed ID: 27580659
[TBL] [Abstract][Full Text] [Related]
42. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
43. Triple-negative breast cancer: molecular subtypes and new targets for therapy.
Lehmann BD; Pietenpol JA; Tan AR
Am Soc Clin Oncol Educ Book; 2015; ():e31-9. PubMed ID: 25993190
[TBL] [Abstract][Full Text] [Related]
44. The Role of Apoptotic Genes and Protein-Protein Interactions in Triple-negative Breast Cancer.
Adinew GM; Messeha S; Taka E; Ahmed SA; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(3):247-272. PubMed ID: 37093683
[TBL] [Abstract][Full Text] [Related]
45. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
46. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
47. MicroRNAs in triple-negative breast cancer.
Koleckova M; Janikova M; Kolar Z
Neoplasma; 2018; 65(1):1-13. PubMed ID: 29322783
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
Ray SK; Mukherjee S
Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
[TBL] [Abstract][Full Text] [Related]
50. MicroRNAs-mediated cell fate in triple negative breast cancers.
Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
[TBL] [Abstract][Full Text] [Related]
51. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY
Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255
[TBL] [Abstract][Full Text] [Related]
52. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
53. Novel genes associated with lymph node metastasis in triple negative breast cancer.
Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
[TBL] [Abstract][Full Text] [Related]
54. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer.
Li Z; Zhang X; Hou C; Zhou Y; Chen J; Cai H; Ye Y; Liu J; Huang N
Int J Oncol; 2020 Feb; 56(2):522-530. PubMed ID: 31894314
[TBL] [Abstract][Full Text] [Related]
56. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
57. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
58. Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women.
Sugita B; Gill M; Mahajan A; Duttargi A; Kirolikar S; Almeida R; Regis K; Oluwasanmi OL; Marchi F; Marian C; Makambi K; Kallakury B; Sheahan L; Cavalli IJ; Ribeiro EM; Madhavan S; Boca S; Gusev Y; Cavalli LR
Oncotarget; 2016 Nov; 7(48):79274-79291. PubMed ID: 27813494
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
60. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
